⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Whitehawk Therapeutics (formerly Aadi Bioscience, Inc.) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Whitehawk Therapeutics (formerly Aadi Bioscience, Inc.)
↗Morristown, New Jersey, USA
Whitehawk Therapeutics is a precision oncology company that recently underwent a strategic pivot and rebranding from Aadi Bioscience. The company has shifted its focus from commercializing its legacy mTOR inhibitor, FYARRO®, to developing a portfolio of novel antibody-drug conjugates (ADCs).
Following a strategic review, the company sold its FYARRO® business and associated infrastructure to Kaken Pharmaceutical. It is now prioritizing the advancement of three preclinical ADC assets licensed from WuXi Biologics and Hangzhou DAC, targeting PTK7, MUC16, and SEZ6, with the goal of reaching clinical trials by 2028.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2011
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$100M (PIPE financing, March 2025)
Investors:Acuta, KVP, Avoro, Venrock, BVF, Vivo, Alta, Rock Springs, RTW, Acorn, Serrado
STOCK
Exchange:NASDAQ
Ticker:WHWK
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Antibody-drug conjugates (ADC)
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:WuXi Biologics (ADC licensing), Hangzhou DAC (ADC licensing), Kaken Pharmaceutical (Purchaser of FYARRO business)
COMPETITION
Position:Emerging
Competitors:Day One Biopharmaceuticals, Kelun-Biotech, Genmab
LEADERSHIP
Key Executives:
Dave Lennon - CEO
David Dornan - Chief Scientific Officer
Scientific Founders:Neil Desai
LINKS
Website:aadibio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Whitehawk Therapeutics (formerly Aadi Bioscience, Inc.). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.